264 related articles for article (PubMed ID: 19776745)
1. p53 ancestry: gazing through an evolutionary lens.
Lu WJ; Amatruda JF; Abrams JM
Nat Rev Cancer; 2009 Oct; 9(10):758-62. PubMed ID: 19776745
[TBL] [Abstract][Full Text] [Related]
2. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
3. When mutants gain new powers: news from the mutant p53 field.
Brosh R; Rotter V
Nat Rev Cancer; 2009 Oct; 9(10):701-13. PubMed ID: 19693097
[TBL] [Abstract][Full Text] [Related]
4. p53 and human cancers.
Lane DP
Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642
[TBL] [Abstract][Full Text] [Related]
5. p53: 800 million years of evolution and 40 years of discovery.
Levine AJ
Nat Rev Cancer; 2020 Aug; 20(8):471-480. PubMed ID: 32404993
[TBL] [Abstract][Full Text] [Related]
6. The p53 tumour suppressor gene and product.
Levine AJ
Cancer Surv; 1992; 12():59-79. PubMed ID: 1638548
[No Abstract] [Full Text] [Related]
7. Early diversification and complex evolutionary history of the p53 tumor suppressor gene family.
Nedelcu AM; Tan C
Dev Genes Evol; 2007 Dec; 217(11-12):801-6. PubMed ID: 17924139
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
9. p53 genes function to restrain mobile elements.
Wylie A; Jones AE; D'Brot A; Lu WJ; Kurtz P; Moran JV; Rakheja D; Chen KS; Hammer RE; Comerford SA; Amatruda JF; Abrams JM
Genes Dev; 2016 Jan; 30(1):64-77. PubMed ID: 26701264
[TBL] [Abstract][Full Text] [Related]
10. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 gain-of-function in cancer.
Oren M; Rotter V
Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
[TBL] [Abstract][Full Text] [Related]
12. Of autophagy and in vivo pancreatic carcinogenesis: the p53 status matters!
Jonckheere N; Vincent A; Van Seuningen I
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):423-5. PubMed ID: 24939064
[TBL] [Abstract][Full Text] [Related]
13. p53 and p53-regulated genes in bladder cancer.
Crew JP; Jones A
BJU Int; 1999 Mar; 83(4):529-30. PubMed ID: 10210595
[No Abstract] [Full Text] [Related]
14. Targeting mutant p53 for cancer therapy.
Oren M; Tal P; Rotter V
Aging (Albany NY); 2016 Jun; 8(6):1159-60. PubMed ID: 27347904
[No Abstract] [Full Text] [Related]
15. The expanding universe of p53 targets.
Menendez D; Inga A; Resnick MA
Nat Rev Cancer; 2009 Oct; 9(10):724-37. PubMed ID: 19776742
[TBL] [Abstract][Full Text] [Related]
16. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
17. The role of p53 in cell cycle regulation.
Shaw PH
Pathol Res Pract; 1996 Jul; 192(7):669-75. PubMed ID: 8880867
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.
Barnes DM; Hanby AM; Gillett CE; Mohammed S; Hodgson S; Bobrow LG; Leigh IM; Purkis T; MacGeoch C; Spurr NK
Lancet; 1992 Aug; 340(8814):259-63. PubMed ID: 1353190
[TBL] [Abstract][Full Text] [Related]
19. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer.
Milner J
Proc Biol Sci; 1991 Aug; 245(1313):139-45. PubMed ID: 1682937
[TBL] [Abstract][Full Text] [Related]
20. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis.
Horvath MM; Wang X; Resnick MA; Bell DA
PLoS Genet; 2007 Jul; 3(7):e127. PubMed ID: 17677004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
